SingleFlowEx CD38 FITC

*Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC: Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994 Nov 1;84 (9) :3017-25., URL: https://pubmed.ncbi.nlm.nih.gov/7524764/, *Zhao YJ, Zhu WJ, Wang XW, Zhang LH, Lee HC: Determinants of the membrane orientation of a calcium signaling enzyme CD38. Biochim Biophys Acta 2015 Sep;1853 (9) :2095-103., URL: https://pubmed.ncbi.nlm.nih.gov/25447548/, *Berthelier V, Laboureau J, Boulla G, Schuber F, Deterre P: Probing ligand-induced conformational changes of human CD38. Eur J Biochem. 2000 May;267 (10) :3056-64., URL: https://pubmed.ncbi.nlm.nih.gov/10806406/, *Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J, Lam CM, Wang XW, Xin D, Zhang P, Koch-Nolte F, Hao Q, Zhang H, Lee HC, Zhao YJ: Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016 Jun 2;6:27055. , URL: https://pubmed.ncbi.nlm.nih.gov/27251573/, *Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F: Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018 Jul 23;7 (10) :e1486948., URL: https://pubmed.ncbi.nlm.nih.gov/30288349/, *Ferrero E, Orciani M, Vacca P, Ortolan E, Crovella S, Titti F, Saccucci F, Malavasi F: Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque. BMC Immunol. 2004 Sep 21;5:21., URL: https://pubmed.ncbi.nlm.nih.gov/15383153/, *Ratuszny D, Skripuletz T, Wegner F, Groß M, Falk C, Jacobs R, Ruschulte H, Stangel M, Sühs KW: Case report: Daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis. Front Neurol. 2020 Dec 22;11:602102., URL: https://pubmed.ncbi.nlm.nih.gov/33414761/, *Verhoeven D, Grinwis L, Marsman C, Jansen MH, van Leeuwen E, Kuijpers TW: B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses. Life Sci Alliance 2023 Jul 7;6 (9) :e202302214., URL: https://pubmed.ncbi.nlm.nih.gov/37419630/, *Shrestha P, Astter Y, Davis DA, Zhou T, Yuan CM, Ramaswami R, Wang HW, Lurain K, Yarchoan R: Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease. Oncoimmunology 2023 Jan 7;12 (1) :2163784., URL: https://pubmed.ncbi.nlm.nih.gov/36632565/

*Cakir-Kiefer C, Muller-Steffner H, Oppenheimer N, Schuber F: Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38 signalling. Biochem J. 2001 Sep 1;358 (Pt 2) :399-406., URL: https://www.ncbi.nlm.nih.gov/pubmed/11513738?ordin, *Lund FE, Muller-Steffner H, Romero-Ramirez H, Moreno-García ME, Partida-Sánchez S, Makris M, Oppenheimer NJ, Santos-Argumedo L, Schuber F: CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism. Int Immunol. 2006 Jul;18 (7) :1029-42., URL: https://www.ncbi.nlm.nih.gov/pubmed/16720618?ordin, *Partida-Sanchez S, Gasser A, Fliegert R, Siebrands CC, Dammermann W, Shi G, Mousseau BJ, Sumoza-Toledo A, Bhagat H, Walseth TF, Guse AH, Lund FE. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol. 2007 Dec 1;179 (11) :7827-39., URL: https://www.ncbi.nlm.nih.gov/pubmed/18025229?ordin